In the last trading session, 28,559,788 shares of the Synthetic Biologics, Inc.(NYSE:SYN) were traded, and its beta was 2.06. Most recently the company’s share price was $0.83, and it changed around -$0.03 or -0.04% from the last close, which brings the market valuation of the company to $60.51 Million. SYN currently trades at a discount to its 52-week high of $1.7, offering almost -104.82% off that amount. The share price’s 52-week low was $0.25, which indicates that the current value has risen by an impressive 69.88% since then. We note from Synthetic Biologics, Inc.’s average daily trading volume that its 10-day average is 22.56 Million shares, with the 3-month average coming to 16.97 Million.
Synthetic Biologics, Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 2.5. If we narrow it down even further, the data shows that none out of 1 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 1 recommended SYN as a Hold, whereas none deemed it a Buy, and no one rated it as Underweight. Synthetic Biologics, Inc. is expected to report earnings per share of -$0.08 for the current quarter.
Synthetic Biologics, Inc. (NYSE:SYN): Trading Information
Although SYN has showed a red trend with a performance of -3.51% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $1.11 on Wednesday, Feb 17 increased the stock’s daily price by 25%. The company’s shares are currently up 1.17% year-to-date, but still down -0.1633 over the last five days. On the other hand, Synthetic Biologics, Inc. (NYSE:SYN) is -0.09% down in the 30-day period. We can see from the shorts that 1.97 Million shares have been sold at a short interest cover period of 0.12 day(s).
The consensus price target as assigned by Wall Street analysts is $1.38, which translates to bears needing to increase their stock price by 66.27% from its current value. Analyst projections state that SYN is forecast to be at a low of $1.25 and a high of $1.5. In order for the stock price to hit the forecast high, the stock would need to surge +80.72% from its current level, while the stock would need to crash 50.6% from its current level to reach the projected low.
Synthetic Biologics, Inc. (SYN) projections and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 38.6%. Synthetic Biologics, Inc. earnings are expected to increase by 75.9% in 2021, but the outlook is negative 0% per year for the next five years.
Synthetic Biologics, Inc. (NYSE:SYN)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 0.37% of Synthetic Biologics, Inc. shares, and 7.12% of them are in the hands of institutional investors. The stock currently has a share float of 7.15%. Synthetic Biologics, Inc. stock is held by 28 institutions, with Renaissance Technologies, LLC being the largest institutional investor. By Dec 30, 2020, it held 6.19% of the shares, which is about 1.24 Million shares worth $474.05 Thousand.
Fisher Asset Management, LLC, with 0.63% or 125.7 Thousand shares worth $48.14 Thousand as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.